-
Sep 23, 2024 | 
healio.com | Jason Laday |Shenaz Bagha |Emmanuel Caeymaex |Joseph F. Merola
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: The FDA has approved bimekizumab-bkzx for three new indications — PsA, AS and non-radiographic axial SpA. The approvals come in the wake of four phase 3 studies.
-
Apr 17, 2024 | 
medscape.com | Alice Gottlieb |Joseph F. Merola
closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. My Alerts You have already selected for My Alerts Add Other Topics Click the topic below to receive emails when new articles are available. Add You've successfully added to your alerts. You will receive email when new content is published.
-
Feb 18, 2024 | 
dermatologytimes.com | Joseph F. Merola |Lauren Buchanan
Joseph Merola, MD, MMSc, dermatologist and rheumatologist at UT Southwestern Medical Center in Dallas, shed light on crucial lupus considerations for dermatologists, marking an exciting era in connective tissue disease management.
-
Nov 23, 2023 | 
emjreviews.com | Diamant Thaçi |Joseph F. Merola |Antonio Costanzo
Presenter: Diamant Thaçi,1Joseph F. Merola,2Antonio Costanzo31. Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Germany2. Harvard Medical School, Brigham and Women’s Hospital, Boston, Massachusetts, USA3.
-
Nov 17, 2023 | 
jofskin.org | Andrew Blauvelt |April Armstrong |Joseph F. Merola |Bruce E. Strober
Main Article Content Keywords bimekizumab, psoriasis, safety, mental health, suicide, suicidality, plaque psoriasis, depression, clinical trial Abstract References 1. Kurd SK et al. Arch Dermatol 2010;146:891–5; 2. Kroenke K et al. J Gen Intern Med 2001;16:606–13; 3. Strober B et al. Br J Dermatol 2023;188:749–59, NCT03598790; 4. Reich K et al. Lancet 2021;397:487–98, NCT03370133; 5. Gordon KB et al. Lancet 2021;397:475–86, NCT03410992; 6. Warren RB et al. N Engl J Med 2021;385:130–41,...
-
Oct 11, 2023 | 
dovepress.com | Joseph F. Merola |Ahmad Amin
Back to Journals » Clinical, Cosmetic and Investigational Dermatology » Volume 17 Authors Merola JF, Amin AZ Received 11 October 2023 Accepted for publication 11 October 2023 Published 5 March 2024 Volume 2024:17 Pages 539—545 DOI https://doi.org/10.2147/CCID.S444221 Checked for plagiarism Yes Editor who approved publication: Dr Scott Fraser Joseph F Merola,1,* Ahmad Z Amin2,* 1Brigham and Women’s Hospital, Boston, Massachusetts, USA; 2Northwestern University Feinberg, School of...
-
Jul 25, 2023 | 
medscape.com | Stanley Cohen |Joseph F. Merola
closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log outCancel This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Stanley Cohen, MD: Hello. I'm Dr Stan Cohen and welcome to Medscape's InDiscussion series on psoriatic arthritis.
-
Jun 8, 2023 | 00965-0/abstract&sz=64)
thelancet.com | Joseph F. Merola |Iain B McInnes
We thank Chirag Rajkumar Kopp and Anupam Wakhlu, and Brandon Smith and colleagues for their interest in the phase 3 BE COMPLETE study,1Merola JF Landewé R McInnes IB et al. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
-
Jun 8, 2023 | 00969-8/abstract&sz=64)
thelancet.com | Iain B McInnes |Joseph F. Merola
Cookie Preference CenterWe use cookies which are necessary to make our site work. We may also use additional cookies to analyse, improve and personalise our content and your digital experience. For more information, see our Cookie Policy and the list of Google Ad-Tech Vendors. You may choose not to allow some types of cookies. However, blocking some types may impact your experience of our site and the services we are able to offer.
-
Jun 7, 2023 | 
jamanetwork.com | Maria C. Schneeweiss |Joseph F. Merola |Richard Wyss |Jonathan I. Silverberg
Key PointsQuestion
What is the background rate of venous thromboembolism (VTE) in patients with bullous pemphigoid in the US? Findings
In this cohort study including 2654 patients with bullous pemphigoid and 26 814 comparator patients, a large-scale analysis of US claims data found a 2-fold increased risk of clinical VTE events in patients with bullous pemphigoid compared with similar patients without the disease.
